1-(2-Bromoethyl)-3-(trifluoromethoxy)benzene | 958027-93-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(2-Bromoethyl)-3-(trifluoromethoxy)benzene
• CAS: 958027-93-5
• 化学式: C₉H₈BrF₃O
• mdl: MFCD11846561
• 分子量: 269.06
• InChiKey: RZHWLCIKYSVRGJ-UHFFFAOYSA-N

物化性质

• 沸点：
  218.3±35.0 °C(Predicted)
• 密度：
  1.530±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-(2,5-dimethoxy-phenylsulfanyl)adenine 、 1-(2-Bromoethyl)-3-(trifluoromethoxy)benzene 生成 8-(2,5-Dimethoxy-phenylsulfanyl)-9-[2-(3-trifluoromethoxy-phenyl)-ethyl]-9H-purin-6-ylamine
  参考文献：
  名称：

  THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER

  摘要：

  本发明涉及公式I-III化合物及其治疗用途。

  公开号：

  US20070299258A1

文献信息

• 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
  申请人：Griffioen Gerard

  公开号：US20140128404A1

  公开（公告）日：2014-05-08

  The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation.

  本发明涉及一种化合物的公式（IA）。本发明还涉及利用公式IA化合物治疗由细胞毒性TAU错误折叠和/或聚集特征的某些神经退行性疾病。
• [EN] 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 1,2,4-THIADIAZOL-5-YLPIPÉRAZINE UTILES DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：REMYND NV

  公开号：WO2013004642A1

  公开（公告）日：2013-01-10

  The present invention relates to a compound of formula (IA) The present invention also relates to the use of the compound of formula IA for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation.

  本发明涉及一种化合物，其化学式为（IA）。本发明还涉及利用化合物IA治疗某些以细胞毒性TAU错误折叠和/或聚集为特征的神经退行性疾病。
• Therapeutic compounds and their use in cancer
  申请人：Myriad Pharmaceuticals, Inc.

  公开号：US07595401B2

  公开（公告）日：2009-09-29

  The invention relates to compounds of Formula I and their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

  本发明涉及I式化合物及其治疗用途，其中取代基A选择自取代或未取代的芳基、杂芳基、杂环基或羧基，取代基B选择自取代或未取代的哌啶基、同哌啶基、吡咯烷基或氮杂环基，R1选择自氢、烷基、芳基、杂芳基氨基和卤素，L1和L2如说明书所定义。
• Purine-core inhibitors of HSP90 and their use in treating cancer
  申请人：Bajji Ashok C.

  公开号：US08476285B2

  公开（公告）日：2013-07-02

  The invention relates to compounds of Formulae I-III: and therapeutic uses thereof, wherein A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carbocyclic group; B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group; R1 is chosen from hydro, alkyl, aryl, heteroaryl, amino, or halo; and L1, L2, are as defined herein.

  本发明涉及I-III式化合物及其治疗用途，其中A选择取代或未取代的芳基，杂芳基，杂环或碳环基；B选择取代或未取代的哌啶，同哌啶，吡咯烷或氮杂环基；R1选择氢、烷基、芳基、杂芳基、氨基或卤素；L1，L2定义如本文所述。
• N-(HETEROCYCLE-METHYL)ALKYLAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND BACTERICIDE
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1391450A1

  公开（公告）日：2004-02-25

  A N-heterocyclicmethyl-alkylamine derivative according to the present invention is a N-heterocyclicmethyl-alkylamine derivative represented by the following general formula (I): or an acid addition salt thereof. [in the formula, R1 represents a heterocycle which has at least one nitrogen atom as a hetero atom and may have a substituent on a ring; R2 represents a hydrogen or the like; R3 represents an alkyl group having a carbon number of 1 to 5 or the like; R4 represents an alkyl group having a carbon number of 1 to 5 or the like; when R4 is an alkyl group having a carbon number of 1 to 5 or a halogenated alkyl group having a carbon number of 1 to 5, carbon atoms in R3 and R4 may be bonded to form a ring structure; m represents an integer of 1 to 3; R5 represents a cycloalkyl group or the like described by the following formula (III): (in the formula, Y and Z each represents a hydrogen atom or the like, the letter p represents an integer of 2 to 5, and the groups described by CYZ may be each the same or different), when m is 1 and R4 is a hydrogen atom, R5 is a cycloalkyl group describedby the foregoing formula (III).]

  根据本发明，N-杂环甲基-烷基胺衍生物是由以下通式（I）代表的 N-杂环甲基-烷基胺衍生物： 或其酸加成盐。 [式中，R1 代表杂环，该杂环至少有一个氮原子作为杂原子，并可在环上有取代基；R2 代表氢或类似物；R3 代表碳原子数为 1 至 5 的烷基或类似物；R4 代表碳原子数为 1 至 5 的烷基或类似物；当 R4 是碳原子数为 1 至 5 的烷基或碳原子数为 1 至 5 的卤代烷基时，R3 和 R4 中的碳原子可以键合形成环状结构；m 代表 1 至 3 的整数；R5 代表下式（III）所述的环烷基或类似基团： (式中，Y 和 Z 分别代表氢原子或类似物，字母 p 代表 2 至 5 的整数，CYZ 所述基团可以相同或不同)，当 m 为 1 且 R4 为氢原子时，R5 为前式(III)所述的环烷基]。